Ananda to attend Benzinga Conference

Ananda Pharma PLC

27 May 2025

 

 27 May 2025

ANANDA PHARMA PLC

("Ananda" or the "Company")

Ananda to attend Benzinga Conference

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that its senior leadership team will be attending the Benzinga Cannabis Capital Conference (the "Benzinga Conference") in Chicago, Illinois on Monday, 9 June and Tuesday 10, June 2025. Ananda will be represented by the Chairman, Charles Morgan, the Chief Executive Officer, Melissa Sturgess, and the Finance Director, Jeremy Sturgess-Smith.

The Benzinga Conference is one of the largest and most influential gatherings of cannabis investors, operators, and policymakers in North America. The presence of Ananda's senior leadership team underscores the Company's commitment to expanding its international profile and building strategic relationships within the global cannabinoid-based pharmaceutical sector.

The team will be available for meetings with investors, potential partners, and media. Please contact the Company ([e-mail]) or Scott Greiper ([e-mail]) to schedule a meeting.

Melissa Sturgess, CEO, commented: "Attending the Benzinga Cannabis Capital Conference presents a valuable opportunity to engage with key stakeholders in the North American cannabis industry. As we continue to make progress with our pharmaceutical programmes, international engagement is increasingly important."

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

For more information please contact:

ANANDA PHARMA PLC	[phone]
	[e-mail]
Chief Executive Officer
Melissa Sturgess
Finance Director
Jeremy Sturgess-Smith
VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper	[phone] [e-mail]
SP ANGEL CORPORATE FINANCE LLP
Corporate Finance	[phone]
Richard Morrison
Josh Ray
Abigail Wayne	[e-mail]
Rob Rees	[e-mail]
YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay	[phone] [e-mail]

https://investors.anandapharma.co.uk/link/4r8Lgr

 

END